array(40) {
  [0]=>
  string(4) "8349"
  ["article_id"]=>
  string(4) "8349"
  [1]=>
  string(179) "Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy"
  ["article_title"]=>
  string(179) "Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy"
  [2]=>
  string(155) "Basel, March 18, 2020 — Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-cla"
  ["short_description"]=>
  string(155) "Basel, March 18, 2020 — Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-cla"
  [3]=>
  string(851) "
Basel, March 18, 2020 — Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-class small interfering RNA (siRNA) investigational agent for hyperlipidemia in adults. The findings were published in two online articles ahead of print in The New England Journal of Medicine. The primary endpoints were achieved in all three trials. Namely, percentage change in LDL-C from baseline to 17 months and time-adjusted percentage change in LDL-C from baseline from 3 through 18 months. This demonstrates that after two starter doses, twice-yearly subcutaneous dosing with inclisiran resulted in durable and potent LDL-C reductions versus placebo. Inclisiran was well-tolerated with a safety profile similar to placebo1, 2.
"
  ["description"]=>
  string(851) "
Basel, March 18, 2020 — Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-class small interfering RNA (siRNA) investigational agent for hyperlipidemia in adults. The findings were published in two online articles ahead of print in The New England Journal of Medicine. The primary endpoints were achieved in all three trials. Namely, percentage change in LDL-C from baseline to 17 months and time-adjusted percentage change in LDL-C from baseline from 3 through 18 months. This demonstrates that after two starter doses, twice-yearly subcutaneous dosing with inclisiran resulted in durable and potent LDL-C reductions versus placebo. Inclisiran was well-tolerated with a safety profile similar to placebo1, 2.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(249) "http://www.globenewswire.com/news-release/2020/03/18/2003008/0/en/Novartis-announces-NEJM-publication-of-three-pivotal-trials-showing-durable-and-potent-efficacy-of-inclisiran-an-investigational-first-in-class-siRNA-cholesterol-lowering-therapy.html"
  ["blog_url"]=>
  string(249) "http://www.globenewswire.com/news-release/2020/03/18/2003008/0/en/Novartis-announces-NEJM-publication-of-three-pivotal-trials-showing-durable-and-potent-efficacy-of-inclisiran-an-investigational-first-in-class-siRNA-cholesterol-lowering-therapy.html"
  [15]=>
  string(19) "2020-03-19 05:01:00"
  ["add_date"]=>
  string(19) "2020-03-19 05:01:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:02"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:02"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8350"
  ["article_id"]=>
  string(4) "8350"
  [1]=>
  string(87) "One Medical and Ascension Texas to Collaborate on Connecting Primary and Specialty Care"
  ["article_title"]=>
  string(87) "One Medical and Ascension Texas to Collaborate on Connecting Primary and Specialty Care"
  [2]=>
  string(150) "Leading healthcare provider organizations will focus on seamless care coordination Leading healthcare provider organizations will focus on seamless ca"
  ["short_description"]=>
  string(150) "Leading healthcare provider organizations will focus on seamless care coordination Leading healthcare provider organizations will focus on seamless ca"
  [3]=>
  string(176) "Leading healthcare provider organizations will focus on seamless care coordination 
Leading healthcare provider organizations will focus on seamless care coordination
"
  ["description"]=>
  string(176) "Leading healthcare provider organizations will focus on seamless care coordination 
Leading healthcare provider organizations will focus on seamless care coordination
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(158) "http://www.globenewswire.com/news-release/2020/03/18/2003002/0/en/One-Medical-and-Ascension-Texas-to-Collaborate-on-Connecting-Primary-and-Specialty-Care.html"
  ["blog_url"]=>
  string(158) "http://www.globenewswire.com/news-release/2020/03/18/2003002/0/en/One-Medical-and-Ascension-Texas-to-Collaborate-on-Connecting-Primary-and-Specialty-Care.html"
  [15]=>
  string(19) "2020-03-19 05:00:00"
  ["add_date"]=>
  string(19) "2020-03-19 05:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:02"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:02"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8351"
  ["article_id"]=>
  string(4) "8351"
  [1]=>
  string(60) "Venus Concept Inc. Announces $22.25 Million Equity Financing"
  ["article_title"]=>
  string(60) "Venus Concept Inc. Announces $22.25 Million Equity Financing"
  [2]=>
  string(166) "TORONTO, March  18, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic"
  ["short_description"]=>
  string(166) "TORONTO, March  18, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic"
  [3]=>
  string(679) "
TORONTO, March  18, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it entered into a definitive agreement for the sale of shares of its common stock, Series A convertible preferred stock and warrants to purchase common stock in a private placement to a group of investors, including EW Healthcare Partners, HealthQuest Capital and SEDCO Capital. The private placement is expected to result in gross proceeds to the Company of approximately $22.25 million, before deducting placement agent fees and other offering expenses.
"
  ["description"]=>
  string(679) "
TORONTO, March  18, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it entered into a definitive agreement for the sale of shares of its common stock, Series A convertible preferred stock and warrants to purchase common stock in a private placement to a group of investors, including EW Healthcare Partners, HealthQuest Capital and SEDCO Capital. The private placement is expected to result in gross proceeds to the Company of approximately $22.25 million, before deducting placement agent fees and other offering expenses.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(129) "http://www.globenewswire.com/news-release/2020/03/18/2002964/0/en/Venus-Concept-Inc-Announces-22-25-Million-Equity-Financing.html"
  ["blog_url"]=>
  string(129) "http://www.globenewswire.com/news-release/2020/03/18/2002964/0/en/Venus-Concept-Inc-Announces-22-25-Million-Equity-Financing.html"
  [15]=>
  string(19) "2020-03-19 04:05:00"
  ["add_date"]=>
  string(19) "2020-03-19 04:05:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:02"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:02"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8425"
  ["article_id"]=>
  string(4) "8425"
  [1]=>
  string(61) "Rapid Diagnostics Firm Secures Financing Amid Covid-19 Crisis"
  ["article_title"]=>
  string(61) "Rapid Diagnostics Firm Secures Financing Amid Covid-19 Crisis"
  [2]=>
  string(153) "&#nlIt might seem like the world has slowed down to a crawl amid the coronavirus (COVID-19) pandemic, but there are still some companies out there raisin"
  ["short_description"]=>
  string(153) "&#nlIt might seem like the world has slowed down to a crawl amid the coronavirus (COVID-19) pandemic, but there are still some companies out there raisin"
  [3]=>
  string(2779) "&#nl
It might seem like the world has slowed down to a crawl amid the coronavirus (COVID-19) pandemic, but there are still some companies out there raising money. E25Bio is one of those companies – bringing in $2 million in funding from Khosla Ventures.
&#nl
The Cambridge, MA-based company develops technology for rapid diagnosis of dangerous infectious diseases such as dengue, zika, and now COVID-19. Financing will go toward research and development, clinical studies, and scaling the company’s launch for diagnostic tests upon receiving Emergency Use Authorization approval.
&#nl
E25Bio’s test is based on technology developed by Dr. Irene Bosch and Dr. Lee Gehrke, the Hermann von Helmholtz Professor of Health Sciences and Technology at MIT. The rapid diagnostic test uses nanoparticle technology to capture virus or viral proteins secreted into the human body.
&#nl
“The same way a hormone is detected on a pregnancy test, our diagnostics provide doctors and patients with results in 15 minutes or less,” Bosch, CTO of E25Bio, said in a release.
&#nl
There are many quickly moving pieces in the COVID-19 outbreak. The diagnostics industry has been rolling out test after test – and MD+DI has reported on these new in vitro diagnostics extensively. Some of the latest companies to grab EUA are Hologic and Quidel.
&#nl
During President Trump and the Coronavirus Task Force’s most recent news conference, kudos were given to both Thermo Fisher Scientific and Roche, some of the first firms to win EUA for tests of the virus. The president also mentioned there would soon be big news coming out of his discussions with FDA.
&#nl
“I’m going to be holding a second news conference … we’re going to talk about the FDA,” Trump said during the news conference. “Some things are happening that are quite exciting.”
&#nl
 
"
  ["description"]=>
  string(2779) "&#nl
It might seem like the world has slowed down to a crawl amid the coronavirus (COVID-19) pandemic, but there are still some companies out there raising money. E25Bio is one of those companies – bringing in $2 million in funding from Khosla Ventures.
&#nl
The Cambridge, MA-based company develops technology for rapid diagnosis of dangerous infectious diseases such as dengue, zika, and now COVID-19. Financing will go toward research and development, clinical studies, and scaling the company’s launch for diagnostic tests upon receiving Emergency Use Authorization approval.
&#nl
E25Bio’s test is based on technology developed by Dr. Irene Bosch and Dr. Lee Gehrke, the Hermann von Helmholtz Professor of Health Sciences and Technology at MIT. The rapid diagnostic test uses nanoparticle technology to capture virus or viral proteins secreted into the human body.
&#nl
“The same way a hormone is detected on a pregnancy test, our diagnostics provide doctors and patients with results in 15 minutes or less,” Bosch, CTO of E25Bio, said in a release.
&#nl
There are many quickly moving pieces in the COVID-19 outbreak. The diagnostics industry has been rolling out test after test – and MD+DI has reported on these new in vitro diagnostics extensively. Some of the latest companies to grab EUA are Hologic and Quidel.
&#nl
During President Trump and the Coronavirus Task Force’s most recent news conference, kudos were given to both Thermo Fisher Scientific and Roche, some of the first firms to win EUA for tests of the virus. The president also mentioned there would soon be big news coming out of his discussions with FDA.
&#nl
“I’m going to be holding a second news conference … we’re going to talk about the FDA,” Trump said during the news conference. “Some things are happening that are quite exciting.”
&#nl
 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(88) "https://www.mddionline.com/rapid-diagnostics-firm-secures-financing-amid-covid-19-crisis"
  ["blog_url"]=>
  string(88) "https://www.mddionline.com/rapid-diagnostics-firm-secures-financing-amid-covid-19-crisis"
  [15]=>
  string(19) "2020-03-19 03:19:35"
  ["add_date"]=>
  string(19) "2020-03-19 03:19:35"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:33"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8304"
  ["article_id"]=>
  string(4) "8304"
  [1]=>
  string(58) "U.S. May Not Have Enough Ventilators for COVID-19 Patients"
  ["article_title"]=>
  string(58) "U.S. May Not Have Enough Ventilators for COVID-19 Patients"
  [2]=>
  string(150) "WEDNESDAY, March 18, 2020 -- There may not be enough ventilators in the United States to cope with the number of novel coronavirus patients who will r"
  ["short_description"]=>
  string(150) "WEDNESDAY, March 18, 2020 -- There may not be enough ventilators in the United States to cope with the number of novel coronavirus patients who will r"
  [3]=>
  string(251) "WEDNESDAY, March 18, 2020 -- There may not be enough ventilators in the United States to cope with the number of novel coronavirus patients who will require them due to pneumonia and other serious respiratory problems, experts say.&#nlAbout 960,000..."
  ["description"]=>
  string(251) "WEDNESDAY, March 18, 2020 -- There may not be enough ventilators in the United States to cope with the number of novel coronavirus patients who will require them due to pneumonia and other serious respiratory problems, experts say.&#nlAbout 960,000..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(193) "https://www.drugs.com/news/u-s-may-not-have-enough-ventilators-covid-19-patients-89042.html?utm_source=ddc&utm_medium=rss&utm_campaign=U.S.+May+Not+Have+Enough+Ventilators+for+COVID-19+Patients"
  ["blog_url"]=>
  string(193) "https://www.drugs.com/news/u-s-may-not-have-enough-ventilators-covid-19-patients-89042.html?utm_source=ddc&utm_medium=rss&utm_campaign=U.S.+May+Not+Have+Enough+Ventilators+for+COVID-19+Patients"
  [15]=>
  string(19) "2020-03-19 03:00:39"
  ["add_date"]=>
  string(19) "2020-03-19 03:00:39"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:42"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8305"
  ["article_id"]=>
  string(4) "8305"
  [1]=>
  string(58) "Most Mass Shooting Events Occur Close to Nontrauma Centers"
  ["article_title"]=>
  string(58) "Most Mass Shooting Events Occur Close to Nontrauma Centers"
  [2]=>
  string(150) "WEDNESDAY, March 18, 2020 -- In 2019, there were 187 mass shooting events, most of which occurred closest to a nontrauma center, according to a resear"
  ["short_description"]=>
  string(150) "WEDNESDAY, March 18, 2020 -- In 2019, there were 187 mass shooting events, most of which occurred closest to a nontrauma center, according to a resear"
  [3]=>
  string(253) "WEDNESDAY, March 18, 2020 -- In 2019, there were 187 mass shooting events, most of which occurred closest to a nontrauma center, according to a research letter published online March 18 in JAMA Surgery.&#nlSage R. Myers, M.D., from the Children's..."
  ["description"]=>
  string(253) "WEDNESDAY, March 18, 2020 -- In 2019, there were 187 mass shooting events, most of which occurred closest to a nontrauma center, according to a research letter published online March 18 in JAMA Surgery.&#nlSage R. Myers, M.D., from the Children's..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(195) "https://www.drugs.com/news/most-mass-shooting-events-occur-close-nontrauma-centers-89046.html?utm_source=ddc&utm_medium=rss&utm_campaign=Most+Mass+Shooting+Events+Occur+Close+to+Nontrauma+Centers"
  ["blog_url"]=>
  string(195) "https://www.drugs.com/news/most-mass-shooting-events-occur-close-nontrauma-centers-89046.html?utm_source=ddc&utm_medium=rss&utm_campaign=Most+Mass+Shooting+Events+Occur+Close+to+Nontrauma+Centers"
  [15]=>
  string(19) "2020-03-19 03:00:20"
  ["add_date"]=>
  string(19) "2020-03-19 03:00:20"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:42"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}